Provided by Tiger Trade Technology Pte. Ltd.

Ironwood Pharmaceuticals

3.06
-0.0900-2.86%
Post-market: 3.080.0180+0.59%19:13 EDT
Volume:1.35M
Turnover:4.16M
Market Cap:497.80M
PE:20.62
High:3.20
Open:3.10
Low:3.03
Close:3.15
52wk High:5.78
52wk Low:0.5271
Shares:162.68M
Float Shares:118.09M
Volume Ratio:0.32
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1484
EPS(LYR):0.1484
ROE:-574.72%
ROA:19.85%
PB:-1.90
PE(LYR):20.62

Loading ...

Ironwood Pharmaceuticals Inc - Hhs Releases Maximum Fair Price for Linzess - SEC Filing

THOMSON REUTERS
·
Nov 26, 2025

Ironwood Pharmaceuticals Inc: Revised Mfp for Linzess Is in Line With Expectations of Co

THOMSON REUTERS
·
Nov 26, 2025

Ironwood Pharma (IRWD) Gets a Hold from Wells Fargo

TIPRANKS
·
Nov 11, 2025

Ironwood Pharmaceuticals, Inc. : Wells Fargo Raises Target Price to $3 From $1

THOMSON REUTERS
·
Nov 11, 2025

Analysts Offer Insights on Healthcare Companies: Genmab (GMAB), Aziyo Biologics (ELUT) and Ironwood Pharma (IRWD)

TIPRANKS
·
Nov 10, 2025

Pagaya Technologies Posts Upbeat Q3 Results, Joins Ironwood Pharmaceuticals, TreeHouse Foods And Other Big Stocks Moving Higher On Monday

Benzinga
·
Nov 10, 2025

Ironwood Pharmaceuticals Shares Jump 27.6% After Q3 Revenue Beat, Outlook Raise

THOMSON REUTERS
·
Nov 10, 2025

Ironwood Pharmaceuticals Q3 Revenue USD 122.06 Million

Reuters
·
Nov 10, 2025

Ironwood Pharmaceuticals reports third quarter 2025 revenue of $122.1 million

Reuters
·
Nov 10, 2025

Ironwood Pharmaceuticals Q3 Basic EPS USD 0.25

THOMSON REUTERS
·
Nov 10, 2025

Ironwood Pharmaceuticals: Engaged in Settlement Negotiations With Ferring Related to Complaint

THOMSON REUTERS
·
Nov 10, 2025

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

THOMSON REUTERS
·
Nov 10, 2025

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD)

TIPRANKS
·
Nov 07, 2025

BRIEF-FDA Approves Linzess Capsules For Children Aged 7 And Older With IBS With Constipation

Reuters
·
Nov 06, 2025

AbbVie, Ironwood Win FDA Approval for Linzess to Treat Children With Irritable Bowel Syndrome With Constipation

MT Newswires Live
·
Nov 06, 2025

FDA: Linzess Recommended Dosage for Pediatric Patients 7 Years and Older With Ibs-C Is 145 Mcg Orally Once Daily

THOMSON REUTERS
·
Nov 06, 2025

FDA: Approved Linzess (Linaclotide) Capsules for Pediatric Patients 7 Years and Older With Irritable Bowel Syndrome With Constipation

THOMSON REUTERS
·
Nov 06, 2025

Ironwood Pharmaceuticals Inc expected to post earnings of 10 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

Craig-Hallum Sticks to Its Hold Rating for Ironwood Pharma (IRWD)

TIPRANKS
·
Oct 29, 2025

Andrew Dreyfus to resign from Ironwood Pharmaceuticals Board following new CEO appointment at NIHCM Foundation

Reuters
·
Oct 10, 2025